Curated News
By: NewsRamp Editorial Staff
October 13, 2026
Nutriband Secures $1.75M from Warrant Exercises to Advance AVERSA Fentanyl
TLDR
- Nutriband raised $1.75 million from warrant exercises to fund AVERSA Fentanyl's NDA, targeting a potential $200 million peak sales market.
- Nutriband's AVERSA technology prevents abuse in transdermal patches, and the company will use warrant proceeds for final clinical development and FDA submission.
- Nutriband's abuse-deterrent fentanyl patch could reduce opioid misuse and accidental exposure, potentially saving lives and improving public health.
- Nutriband's AVERSA Fentanyl patch, with abuse-deterrent technology, might become the first of its kind and could earn up to $200 million annually.
Impact - Why it Matters
This news matters because the $1.75 million in proceeds provides critical funding for Nutriband to advance AVERSA Fentanyl, a potential first-in-class abuse-deterrent opioid patch, through late-stage clinical development and toward FDA submission. If approved, AVERSA Fentanyl could address the ongoing opioid crisis by reducing abuse and misuse, while also offering a significant commercial opportunity with estimated peak annual U.S. sales of $80 million to $200 million. For investors, the elimination of remaining warrants simplifies the capital structure and signals confidence in the company’s pipeline, potentially enhancing shareholder value.
Summary
Nutriband (NASDAQ: NTRB) has announced that 272,671 NTRBW warrants were exercised at a strike price of $6.43, generating approximately $1.75 million in proceeds. These warrants expired on September 30 without extension, leaving the company with no remaining tradable warrants. The proceeds will primarily fund the remaining clinical development of AVERSA Fentanyl and the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval. AVERSA Fentanyl is a potential first-of-its-kind opioid patch with abuse-deterrent properties, and a 2022 Health Advances market analysis estimates peak annual U.S. sales of $80 million to $200 million. For the full press release, visit https://ibn.fm/ZUBic.
Nutriband Inc. focuses on developing a portfolio of transdermal pharmaceutical products. Its lead product is an abuse-deterrent fentanyl patch incorporating the company’s AVERSA(TM) technology. This technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company’s website is www.nutriband.com. Investors can find the latest news and updates relating to NTRB in the company’s newsroom at https://ibn.fm/NTRB.
MissionIR is a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Secures $1.75M from Warrant Exercises to Advance AVERSA Fentanyl
